About
What it is and where it shows up.
Low sodium salt is a salt substitute in which a portion of sodium chloride (NaCl) is replaced with potassium chloride (KCl) and/or other mineral salts such as magnesium chloride, reducing overall sodium content while maintaining salty taste. It is used as a direct table-salt replacement and in food manufacturing to help consumers lower dietary sodium intake and reduce the risk of hypertension and cardiovascular disease.
Safety summary
The regulatory and scientific consensus.
The primary substituent, potassium chloride (E 508), carries an ADI of 'not specified' from both EFSA (2019) and JECFA, indicating no quantitative safety concern for the general healthy population. However, individuals with impaired renal function cannot adequately excrete excess potassium, creating a clinically significant risk of hyperkalemia and adverse cardiac effects. India's FSSAI mandates a 'To be consumed under medical supervision' advisory on all low sodium salt products, reflecting these sensitive-population concerns.
Regulatory landscape
What food-safety regulators have decided.
| Jurisdiction | Status | Note |
|---|---|---|
| EFSA (European Food Safety Authority) (European Union) | Approved | Potassium chloride (E 508), the principal substituent, is authorised under Annex II and III to Regulation (EC) No 1333/2008 and re-evaluated by EFSA's FAF Panel in 2019 with ADI confirmed as 'not specified'; use is quantum satis in most food categories. A novel food application for a potassium–magnesium mineral salt (Salona®/carnallite-based) as a low-sodium salt substitute is under review under Regulation (EU) 2015/2283; EFSA NDA Panel (2024) found no nutritional or safety concerns at proposed use levels. EU Regulation 1169/2011 requires mandatory nutrition labelling of salt content on prepacked foods.source |
| FSSAI (Food Safety and Standards Authority of India) (India) | Approved | FSS (Food Product Standards and Food Additives) Regulations 2011, Section 2.9.30 (Version 2, Nov 2024): sodium content of salt substitutes shall not exceed 120 mg per 100 g of the mixture. A 2021 FSSAI draft notification defined LSS as containing 60–75% sodium chloride. Labels must bear the declaration 'low sodium salt substitute' or 'low sodium dietetic salt' and must declare cation content (sodium, potassium, calcium, magnesium, ammonium, choline per 100 g). The advisory 'To be consumed under medical supervision' is mandatory. Individual branded products (e.g., Saltwell Natural and Saltwell Microfine/Regular) have been separately approved under FSS (Approval for Non-Specified Food and Food Ingredients) Regulations, 2017.source |
| FDA (Food and Drug Administration) (United States) | Approved | The principal sodium substitute, potassium chloride, is affirmed as GRAS under 21 CFR 184.1622. No specific ADI or maximum use level is codified for the low sodium salt mixture; use is governed by good manufacturing practice (GMP). FDA's voluntary sodium-reduction guidance covers 163 processed food categories but does not set a mandatory ceiling on salt substitutes. |
Who should approach with care
Whose guidance would steer them away.
Kidney Disease — Impaired renal potassium excretion in chronic kidney disease patients means additional dietary potassium from KCl-based salt substitutes can cause dangerous hyperkalemia; even modest doses of 1 g potassium above dietary intake have been associated with elevated plasma potassium and adverse effects in subjects with reduced kidney function (UK COT / EFSA assessment of potassium-based replacers).
Heart Disease — Supplemental potassium doses of 5–7 g/day can cause adverse effects on cardiac function even in apparently healthy subjects; patients with existing heart disease or those on cardiac medications should obtain medical advice before regular use.
Hypertension — Patients with hypertension on ACE inhibitors, angiotensin-receptor blockers, or potassium-sparing diuretics face increased risk of hyperkalemia from the extra potassium load provided by low sodium salt substitutes.
Infants — Low sodium salt substitutes are not intended for infants; immature kidneys have limited capacity to handle potassium loads, and EU novel food assessment (EFSA 2024) for mineral-salt substitutes explicitly excludes infants from approved target groups.
Research citations
The sources behind this verdict.
- 1FDA. 21 CFR 184.1622 — Potassium Chloride (GRAS Affirmation). accessdata.fda.gov
- 2FSSAI. Food Safety and Standards (Food Product Standards and Food Additives) Regulations, 2011 — Chapter 2.9: Salt, Spices, Condiments and Related Products (Version 2, November 2024), 2024. fssai.gov.in
- 3EFSA. Safety of mineral salt containing potassium and magnesium as a novel food pursuant to Regulation (EU) 2015/2283, 2024. pmc.ncbi.nlm.nih.gov
- 4PubMed. India's tryst with salt: Dandi march to low sodium salts, 2023. pmc.ncbi.nlm.nih.gov
- 5EFSA. Re-evaluation of hydrochloric acid (E 507), potassium chloride (E 508), calcium chloride (E 509) and magnesium chloride (E 511) as food additives, 2019. efsa.europa.eu
Independently researched5 citations